High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized...

Area of Science:

• Neurology
• Endocrinology
• Bone Metabolism

Background:

• Multiple sclerosis (MS) patients face increased risks of osteoporosis and fractures.
• Poor vitamin D status is a risk factor for MS and may impact bone health.
• Vitamin D supplementation is often recommended for MS patients to manage progression and bone health.

Purpose of the Study:

• To evaluate the impact of high-dose weekly vitamin D3 supplementation on bone metabolism markers in individuals with relapsing-remitting MS.
• To assess the effect of vitamin D on bone formation and resorption in MS patients.

Main Methods:

• A randomized controlled trial involving 68 relapsing-remitting MS patients.
• Participants received either 20,000 IU of vitamin D3 weekly or a placebo for 96 weeks.
• Biochemical markers of bone metabolism, including PINP and CTX1, were measured.

Main Results:

• Vitamin D supplementation significantly increased serum 25-hydroxyvitamin D levels and decreased parathyroid hormone.
• No significant effect was observed on bone formation markers (PINP) or bone resorption markers (CTX1).
• Neither PINP nor CTX1 levels predicted bone loss over the 96-week study period.

Conclusions:

• Weekly high-dose vitamin D supplementation does not appear to prevent bone loss in MS patients.
• Findings align with previous studies showing no effect on bone mass density in the same patient cohort.
• Vitamin D supplementation may not be effective for preventing bone loss in MS patients unless they have a vitamin D deficiency.